NVO241122C128000
- 0.15
- -0.30-66.67%
Novo-Nordisk A/S Newsroom
Weight-reducing version of semaglutide lands in the Chinese market! Novo Nordisk (NVO.US) unlocks new growth engine.
novo-nordisk a/s launched Wegovy in china at a price lower than in the usa; this is an important step for the company to increase its investment in the rapidly growing market in china.
Sector Update: Health Care Stocks Mixed in Afternoon Trading
Top Midday Stories: Spirit Airlines Files for Chapter 11 Bankruptcy Protection; Trump Team Looking to Ease Rules for Self-Driving Cars
European Equities Traded in the US as American Depositary Rise in Monday Trading
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
The first prescription of Semaglutide for weight reduction was given to patients with a 15-year history of obesity. Experts remind that weight loss drugs are not suitable for everyone.
According to Yicai, on the second day of the official commercial launch of novo-nordisk A/S's long-term weight management glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide weekly preparation novo-yang in China, the first prescription in a public hospital nationwide was issued at Shanghai Fudan University Zhongshan Hospital Endocrinology Department. Currently, several top-tier hospitals in Shanghai have expressed to reporters that they can prescribe novo-yang, and drug supply is also catching up. However, experts remind that weight loss medications are not suitable for everyone, only patients who meet the criteria can use the medication. The Deputy Director of the Endocrinology Branch of the Chinese Medical Association, Fudan.
Market Chatter: Eli Lilly, Novo Nordisk Obesity Drugs Covered Mostly by Medicaid, Analysts Say
'Novo Nordisk Launches Wegovy in China With Prices Well Below US' - Bloomberg News
Express News | Barclays analyst: The pharmaceutical industry is expected to face more challenges in 2025.
Pharmaceutical Sector Outlook for 2025 Looks Rocky -- Market Talk
The key factors influencing novo-nordisk a/s stock price: the data for the next-generation weight loss drug will be released next month.
Novo Nordisk will release the final clinical trial data of its "next-generation" weight loss drug CagriSema next month. It is expected that CagriSema will be able to reduce the weight of users by 25% in a little over a year, potentially dominating the leading position of GLP-1 class weight loss drugs.
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? -- Heard on the Street -- WSJ
Express News | How is the pricing for novo-nordisk a/s's GLP-1 weight loss drug officially entering China?
Novo-nordisk a/s: The company has begun applying for the provincial bidding registration of NovoSeven.
According to 21st Century Business Herald on November 17th, Novo Nordisk has indicated that the company has started applying for the provincial bidding of NovoYing, and the specific pricing can refer to the bidding price. After the listing, Novo Nordisk will cover public hospitals, private hospitals, pharmacies and other channels nationwide based on the distribution of obese patients.
Express News | The weight loss version of semaglutide has officially launched in china.
Duan Yongping and Buffett have a "soul resonance" in their third-quarter operations, and Li Lu re-enters an oil & gas stock.
For nvidia, Bridgewater, Jinglin, Baillie Gifford, and "Cathie Wood" are all reducing their shareholding, and everyone is quietly united in missing the opportunity of nvidia reaching the top of the market cap.
US Manufacturing Index Rises To 43, Highest Since 2020
The "most lethal in history" nomination of the usa Secretary of Health! Vaccine stocks have been plummeting for consecutive days, and Kennedy has been criticized as the number one threat to public health.
On Friday, biontech once fell nearly 9%, moderna fell over 7%, and nasdaq biotechnology index dropped over 4%. Industry insiders said that Kennedy's 'junk science' poses a huge threat to public health.